Sign in

You're signed outSign in or to get full access.

Kendall Forbes

Executive Vice President, Sales & Operations at Guardian Pharmacy Services
Executive

About Kendall Forbes

Kendall Forbes is Executive Vice President, Sales & Operations at Guardian Pharmacy Services (GRDN), serving since the company’s founding in 2004; he is 68 years old and holds a B.S. from the University of Louisiana Monroe School of Pharmacy and completed a graduate fellowship in Radiopharmacy at the University of New Mexico . Company performance metrics tied to his 2024 incentive program achieved targets of $1.228 billion revenue, $90.8 million Adjusted EBITDA, and 186,000 residents served in December 2024, resulting in a 100% payout of target annual cash incentives . Forbes is one of the “Guardian Founders” with significant ownership and voting power under the Stockholders’ Agreement, contributing to GRDN’s “controlled company” status at NYSE .

Past Roles

OrganizationRoleYearsStrategic Impact
Central Pharmacy Services, Inc.Co‑founder; Executive Vice President of Operations1993–2004 Venture ultimately acquired by Cardinal Health, Inc. in 2001, evidencing scaled operational execution
Baton Rouge Central PharmacyOwner1985–1993 Built and operated regional pharmacy platform
Nuclear Pharmacy, Inc. (predecessor to Syncor Nuclear Pharmacy)Pharmacy Manager1982–1985 Radiopharmacy expertise foundational to later leadership in pharmacy operations

External Roles

  • No public company board or external directorships disclosed for Forbes in reviewed filings .

Fixed Compensation

Metric20232024
Base Salary ($)$348,625 $400,000
Bonus ($)$0 $0
Non‑Equity Incentive Plan Compensation ($)$184,313 $240,000
All Other Compensation ($)$50,687 $41,050 (includes $12,075 401(k) match and $28,975 self‑employment tax reimbursement)
Total ($)$583,625 $681,050
  • Employment Agreement base salary set at $400,000, effective September 27, 2024; target annual cash incentive opportunity no less than 60% of base salary; maximum no less than 150% of target .

Performance Compensation

2024 Annual Cash Incentive – Metrics, Targets, Actuals, Payout

MetricTargetActualPayout
Company Revenue$1.175 billion $1.228 billion 100% of target award
Company Adjusted EBITDA$86.1 million $90.8 million 100% of target award
Residents Served (Dec 2024)177,000 186,000 100% of target award
  • 2024 payout approved at 100% of target: $240,000 to Forbes .

2025 Annual Incentive Program – Design

ElementDetail
Metrics & WeightingRevenue 20%; Adjusted EBITDA 60%; Geographic Expansion 20%
Payout CurveThreshold 75% of target; Target 100%; Maximum 125%
Award Opportunity (Forbes)Threshold $185,400; Target $247,200; Maximum $309,000

2025 Long‑Term Incentive (RSUs)

Grant DateGrant ValueVestingAcceleration
Feb 5, 2025$240,000 RSUs Cliff vesting in full on Feb 5, 2028 Full vesting upon death, disability, or change‑in‑control
  • No equity awards outstanding as of Dec 31, 2024 .

Equity Ownership & Alignment

HoldingShares% of ClassCombined Voting Power
Class A Common608,570 2.7% of Class A outstanding 3.8% combined voting power
Class B Common1,825,710 4.5% of Class B outstanding 3.8% combined voting power
Total Beneficial2,434,280 (sole voting and dispositive power) 3.8% combined voting power
  • Insider trading policy prohibits hedging; pledging is not expressly addressed in reviewed disclosure .
  • No executive stock ownership guidelines disclosed; non‑employee directors must hold 5x annual cash retainer and retain 100% of shares from RSU settlements until compliant .
  • Controlled company status: the Guardian Founders, including Forbes, hold a majority of voting power, exempting GRDN from certain NYSE governance requirements .

Employment Terms

TermProvision
Agreement Effective DateSeptember 27, 2024
Initial Term & Auto‑RenewalInitial term ends on second anniversary; auto‑extends annually unless 60‑day non‑renewal notice
Base Salary$400,000
Target & Max BonusTarget ≥60% of base; Maximum ≥150% of target
Severance (non‑CoC)2× (base + target bonus) cash; prorated target bonus; health premium reimbursement up to 24 months; subject to release
Severance (within 2 years post‑CoC)3× (base + target bonus) cash; prorated target bonus; health premium reimbursement up to 36 months; full vesting of equity (performance awards vest at greater of target or actual)
Restrictive CovenantsCustomary non‑competition, non‑solicitation, confidentiality
Clawback3‑year recovery of incentive‑based comp upon required restatement; fault not required, with limited exceptions per SEC/NYSE

Investment Implications

  • Alignment: Forbes’ 2.434 million share beneficial ownership and 3.8% combined voting power provide meaningful skin‑in‑the‑game; GRDN’s controlled company status indicates founder influence over governance and strategic outcomes .
  • Incentive mix and performance focus: Annual incentives are materially tied to Adjusted EBITDA and revenue, with 2025 weighting 60% to Adjusted EBITDA, reinforcing margin/cash‑flow discipline; 2024 targets were met at 100% payout .
  • Vesting and potential selling pressure: 2025 RSUs have a single cliff on Feb 5, 2028 with full vesting and change‑in‑control acceleration, creating a discrete future vesting event rather than ongoing sell pressure; no options outstanding as of 2024 reduces near‑term exercise‑driven sales .
  • Retention/CoC economics: Double‑trigger change‑in‑control benefits at 3× cash plus equity acceleration and extended benefits increase transaction costs and retention stickiness; non‑CoC severance at 2× supports retention but adds cost if turnover occurs .
  • Governance risk mitigants: Hedging is prohibited and a formal clawback is in place; pledging not disclosed; lack of executive ownership guidelines and controlled company exemptions may reduce external governance checks, warranting monitoring of compensation rigor and capital allocation .

No related party transactions involving Forbes were reported in 2023–2024 beyond a directed share program purchase by a director; Audit Committee policy governs future related‑party reviews .